8-K: Surmodics Reports Mixed Q1 2025 Results Amidst Pending Acquisition

Surmodics reported a slight revenue decrease and a larger net loss for the first quarter of fiscal year 2025, while navigating a pending acquisition by GTCR.

Summary

• Surmodics announced its financial results for the first quarter of fiscal year 2025, which ended December 31, 2024.
• Total revenue decreased by 2% year-over-year to $29.9 million.
• Excluding SurVeil drug-coated balloon license fee revenue, total revenue decreased by 3% to $28.7 million.
• The company reported a GAAP net loss of $(3.7) million, compared to a loss of $(0.8) million in the prior-year period.
• Adjusted EBITDA was $3.6 million, down from $3.9 million in the same period last year.
• Medical device revenue decreased by 1% to $23.3 million, with a 15% decrease in product sales partially offset by a 14% increase in performance coating royalties.
• In Vitro Diagnostics revenue decreased by 5% to $6.6 million due to unfavorable order timing.
• The company's cash and investments decreased by $10.0 million during the quarter, ending at $30.1 million.
• The pending acquisition by GTCR for $43.00 per share, valuing the company at approximately $627 million, is still underway, with the goal of closing in the second fiscal quarter ending March 31, 2025.

Sentiment

Score: 4

Explanation: The document presents mixed results with a significant increase in net loss and a decrease in revenue, offset by some positive developments in specific product lines and the pending acquisition. The overall tone is cautious due to the ongoing merger process and regulatory uncertainties.

Positives

• Medical device performance coating royalties and license fee revenue increased by 14%, driven by the Serene hydrophilic coating.
• The Pounce XL Thrombectomy System received FDA 510(k) clearance, expanding its market reach.
• The PROWL registry study showed strong early results for the Pounce Thrombectomy System with 96.8% procedural flow restoration.
• The company is actively working towards completing the merger with GTCR in the second fiscal quarter of 2025.

Negatives

• Total revenue decreased by 2% year-over-year.
• GAAP net loss significantly increased to $(3.7) million from $(0.8) million in the prior year.
• Medical device product sales decreased by 15%, primarily due to lower SurVeil DCB revenue.
• In Vitro Diagnostics revenue decreased by 5% due to unfavorable order timing.
• Operating costs and expenses increased by 13%, driven by merger-related charges.
• Cash and investments decreased by $10.0 million during the quarter.

Risks

• The pending merger with GTCR is subject to regulatory approval and may not be completed within the anticipated timeframe or at all.
• The company's stock price may decline if the merger is not completed.
• The company may be required to pay a termination fee of $20.38 million if the merger agreement is terminated under certain circumstances.
• The merger process may disrupt the company's operations and business relationships.
• The company faces risks related to the commercialization of its products, including the SurVeil DCB.
• The company is reliant on third parties for the development, approval, and marketing of products incorporating its technologies.
• The company is subject to supply chain constraints and market conditions that could impact cash flows.

Future Outlook

Surmodics is not providing financial guidance for fiscal year 2025 due to the pending acquisition by GTCR. The company aims to complete the merger in the second fiscal quarter ending March 31, 2025, subject to regulatory approvals.

Management Comments

• Gary Maharaj, President and CEO of Surmodics, Inc., stated that the company delivered strong growth in revenue from medical device performance coatings royalties and sales of the Pounce thrombectomy platforms.
• Mr. Maharaj also acknowledged the efforts of the Surmodics team in achieving financial performance and operational progress while working to comply with the FTC's Second Request.

Industry Context

The medical device industry is seeing a mix of growth and challenges, with some companies experiencing increased demand for specific products while others face headwinds from supply chain issues and regulatory hurdles. Surmodics' performance reflects these trends, with growth in some areas offset by declines in others. The pending acquisition by GTCR is part of a broader trend of private equity firms investing in the healthcare sector.

Comparison to Industry Standards

• Surmodics' revenue decline of 2% is slightly worse than some of its peers in the medical device sector, which have reported flat or modest growth in the same period. For example, companies like Medtronic and Boston Scientific have shown more resilience in their core businesses.
• The 15% decrease in medical device product sales is significant and highlights the impact of the SurVeil DCB stocking order timing. This contrasts with companies like Abbott, which have seen more consistent sales in their cardiovascular device segments.
• The 14% growth in performance coating royalties is a positive sign and aligns with the trend of increasing adoption of advanced coating technologies in medical devices. This is comparable to companies like DSM and Hydromer, which specialize in advanced materials for medical applications.
• The adjusted EBITDA of $3.6 million is lower than some of its competitors, indicating potential challenges in profitability. Companies like Stryker and Zimmer Biomet have reported higher EBITDA margins due to their scale and diversified product portfolios.
• The pending acquisition by GTCR is similar to other private equity deals in the healthcare space, where firms are looking to leverage their expertise to improve operational efficiency and drive growth. This is a common strategy in the current market environment.

Stakeholder Impact

• Shareholders are awaiting the completion of the merger with GTCR, which will result in a cash payment of $43.00 per share.
• Employees are navigating the uncertainty of the pending acquisition and its potential impact on their roles.
• Customers are continuing to utilize Surmodics' products and technologies, with growth in performance coating royalties.
• Suppliers are likely monitoring the merger process and its potential impact on their business relationships with Surmodics.
• Creditors are aware of the company's debt obligations and the pending merger, which will likely impact the company's financial structure.

Next Steps

• The company will continue to work towards completing the merger with GTCR in the second fiscal quarter ending March 31, 2025.
• Surmodics will continue to engage with the FTC to secure the necessary approvals for the merger.
• The company will focus on growing its medical device performance coating royalties and sales of the Pounce thrombectomy platform.
• Surmodics will continue to monitor and manage its supply chain and operating expenses.

Key Dates

Keywords

Surmodics, GTCR, Merger, Medical Devices, In Vitro Diagnostics, Thrombectomy, FDA Clearance, Financial Results, Revenue, EBITDA, Net Loss, Pounce Thrombectomy System, SurVeil DCB, Performance Coatings